¿¬¼ö°­ÁÂ
2024 ´ëÇÑÄ¡¸ÅÇÐȸ Ãá°è Çмú´ëȸ : 2024-04-20

2024 ´ëÇÑÄ¡¸ÅÇÐȸ Ãá°è Çмú´ëȸ : 2024-04-20
±³À°ÀÏÀÚ : 2024-04-20
±³À°Àå¼Ò : ¹é¹ü±è±¸±â³ä°ü

±³À°ÁÖÁ¦ : 2024 ´ëÇÑÄ¡¸ÅÇÐȸ Ãá°è Çмú´ëȸ

ÁÖÃÖ±â°ü : ´ëÇÑÄ¡¸ÅÇÐȸ
´ã´çÀÚ : ±èÁÖ¿Á
¿¬¶ôó : 02-587-7462  

À̸ÞÀÏ : secretkda@thedementia.co.kr

±³À°Á¾·ù : ½Å°æ°ú

Âü¼®¿¹»óÀÎ : 300¸í
Èñ¸ÁÆòÁ¡ : 6Á¡

Áö¿ª : ¼­¿ïƯº°½Ã
±³À°½Ã°£ : 9 ½Ã°£ 40ºÐ

¼¼ºÎ¼ö°­·á : 120,000¿ø  

ºñ°í »çÀüµî·Ï: ÀϹÝȸ¿ø 4¸¸¿ø, Á¤È¸¿ø 6¸¸¿ø, ºñȸ¿ø 11¸¸¿ø / ´çÀϵî·Ï: ÀϹÝȸ¿ø 5¸¸¿ø, Á¤È¸¿ø 7¸¸¿ø, ºñȸ¿ø 12¸¸¿ø


±¸ºÐ ¿ùÀÏ °­ÀÇ½Ç ½Ã°£ ±³À°Á¦¸ñ °­»ç¸í(¼Ò¼Ó) Çʼö°ú¸ñ

±âŸ 04¿ù 20ÀÏ ¹é¹ü±è±¸±â³ä°ü 08:50~09:00 Opening Remarks À±¿µÃ¶(´ëÇÑÄ¡¸ÅÇÐȸÀå)

±³À°½Ã°£ 04¿ù 20ÀÏ ¹é¹ü±è±¸±â³ä°ü (Room A) 09:00~09:20 Elecsys AD CSF biomarker best practice sharing of other countries Cristiano Tunesi(Roche Diagnostics International)

±³À°½Ã°£ 04¿ù 20ÀÏ ¹é¹ü±è±¸±â³ä°ü (Room A) 09:20~09:40 Lecanemab in Early Alzheimer¡¯s Disease: Tau PET, Long-Term Outcomes, and Subcutaneous Formulation Michael Irizarry(Eisai)

±³À°½Ã°£ 04¿ù 20ÀÏ ¹é¹ü±è±¸±â³ä°ü (Room A) 09:40~10:00 Baseline Characteristics Associated with Achieving Rapid Amyloid Plaque Clearance Following Donanemab Treatment Saygin Gonderten(Lilly)

ÈÞ½Ä 04¿ù 20ÀÏ ¹é¹ü±è±¸±â³ä°ü 10:00~10:20 Coffee Break ()

±³À°½Ã°£ 04¿ù 20ÀÏ ¹é¹ü±è±¸±â³ä°ü (Room A) 10:20~11:10 Monoclonal antibodies: how to apply the new hope in clinics ¾çµ¿¿ø(°¡Å縯ÀÇ´ë)

±³À°½Ã°£ 04¿ù 20ÀÏ ¹é¹ü±è±¸±â³ä°ü (Room A) 11:10~12:00 Insights into mechanisms of ARIA from preclinical models - 20 years of research Donna M. Wilcock(Indiana University)

±âŸ 04¿ù 20ÀÏ ¹é¹ü±è±¸±â³ä°ü (Room A) 12:00~13:00 ÃÑȸ ()

Åä·Ð 04¿ù 20ÀÏ ¹é¹ü±è±¸±â³ä°ü 13:00~14:00 Poster Presentation ()

±³À°½Ã°£ 04¿ù 20ÀÏ ¹é¹ü±è±¸±â³ä°ü (Room A) 14:00~14:12 [±¸¿¬] Enhancement of glymphatic activity in early Alzheimer¡¯s disease using low-intensity ultrasound treatment ±èÀçÈ£(ÇѸ²´ëÇб³µ¿Åº¼º½Éº´¿ø)

±³À°½Ã°£ 04¿ù 20ÀÏ ¹é¹ü±è±¸±â³ä°ü (Room A) 14:12~14:24 [±¸¿¬] Evaluation of Efficacy and Safety of Low Dose Ionizing Radiation Therapy on Alzheimer¡¯s Disease: Interim Results of Multicenter Randomized, Single Blind, Phase II Clinical Trial Á¤¿ø±Ô(°­µ¿°æÈñ´ëÇб³º´¿ø)

±³À°½Ã°£ 04¿ù 20ÀÏ ¹é¹ü±è±¸±â³ä°ü (Room A) 14:24~14:36 [±¸¿¬] Effectiveness of personalized hippocampal network-targeted stimulation in Alzheimer¡¯s disease: A randomized controlled trial Á¤¿µÈñ(¸íÁöº´¿ø)

±³À°½Ã°£ 04¿ù 20ÀÏ ¹é¹ü±è±¸±â³ä°ü (Room A) 14:36~14:48 [±¸¿¬] The Efficacy of a Home-Based, Augmented Reality Dual-Task Platform for Cognitive-Motor Training in Elderly Patients: A Pilot Observational Study À±º¸¶ó(°¡Å縯´ëÇб³ ¼­¿ï¼º¸ðº´¿ø)

±³À°½Ã°£ 04¿ù 20ÀÏ ¹é¹ü±è±¸±â³ä°ü (Room A) 14:48~15:00 [±¸¿¬] Presence of gait improvement 1 month after the CSF tap test in idiopathic normal pressure hydrocephalus ±è¹ÎÁÖ(ºÐ´ç¼­¿ï´ëÇб³º´¿ø)

ÈÞ½Ä 04¿ù 20ÀÏ ¹é¹ü±è±¸±â³ä°ü (Room A) 15:00~15:10 Coffee Break ()

±³À°½Ã°£ 04¿ù 20ÀÏ ¹é¹ü±è±¸±â³ä°ü (Room A) 15:10~15:30 Treatment-tailored cognitive change detection À̺´È­(»ï¼º¼­¿ïº´¿ø)

±³À°½Ã°£ 04¿ù 20ÀÏ ¹é¹ü±è±¸±â³ä°ü (Room A) 15:30~15:50 Treatment-tailored ADL and behavioral change detection ¹é¹ÎÀç(ºÐ´ç¼­¿ï´ëÇб³º´¿ø)

±³À°½Ã°£ 04¿ù 20ÀÏ ¹é¹ü±è±¸±â³ä°ü (Room A) 15:50~16:10 Early neuropsychological parallel intervention: Process-based cognitive training on memory ½Å¹Î¿µ(¼­¿ï»ó´ã½É¸®´ëÇпø´ëÇб³)

±³À°½Ã°£ 04¿ù 20ÀÏ ¹é¹ü±è±¸±â³ä°ü (Room A) 16:10~16:30 An area of superficial siderosis ÀåÇý¹Î(¼­¿ï´ëÇб³º´¿ø)

±³À°½Ã°£ 04¿ù 20ÀÏ ¹é¹ü±è±¸±â³ä°ü (Room A) 16:30~16:50 >4 microhemorrhages ¼­»ó¿ø(¼º±Õ°üÀÇ´ë)

±³À°½Ã°£ 04¿ù 20ÀÏ ¹é¹ü±è±¸±â³ä°ü (Room A) 16:50~17:10 Anticoagulants and tPA ÀÓÀ缺(¿ï»êÀÇ´ë)

±³À°½Ã°£ 04¿ù 20ÀÏ ¹é¹ü±è±¸±â³ä°ü (Room B) 14:00~14:12 [±¸¿¬] TDP-43 Oligomers in Neurodegenerative diseases: AD and SD ¾È¼º¼ö(°¡Ãµ´ëÇб³)

±³À°½Ã°£ 04¿ù 20ÀÏ ¹é¹ü±è±¸±â³ä°ü (Room B) 14:12~14:24 [±¸¿¬] Downregulation of Mest facilitate the progression of AD pathophysiology Á¶ÀÍÈÆ(¼­¿ï½Ã¸³´ë »ý¸í°úÇаú)

±³À°½Ã°£ 04¿ù 20ÀÏ ¹é¹ü±è±¸±â³ä°ü (Room B) 14:24~14:36 [±¸¿¬] Identification of genetic risk loci and risk prediction for ¥â-amyloid deposition in East Asian population ±èÁØÇ¥(»ï¼º¼­¿ïº´¿ø)

±³À°½Ã°£ 04¿ù 20ÀÏ ¹é¹ü±è±¸±â³ä°ü (Room B) 14:36~14:48 [±¸¿¬] Discordance Between Plasma AD Biomarkers and A¥â PET in Memory Clinic: Prevalence and Clinical Consequences À±Áöȯ(»ï¼º¼­¿ïº´¿ø)

±³À°½Ã°£ 04¿ù 20ÀÏ ¹é¹ü±è±¸±â³ä°ü (Room B) 14:48~15:00 [±¸¿¬] White Matter Hyperintensities and Cholinergic Degeneration as Lewy Body Disease °­¼º¿ì(¼¼ºê¶õ½ºº´¿ø)

ÈÞ½Ä 04¿ù 20ÀÏ ¹é¹ü±è±¸±â³ä°ü (Room B) 15:00~15:10 Coffee Break ()

±³À°½Ã°£ 04¿ù 20ÀÏ ¹é¹ü±è±¸±â³ä°ü (Room B) 15:10~15:30 Ä¡¸Å°ü¸®ÁÖÄ¡ÀÇ ½Ã¹ü»ç¾÷ ÃÖÈ£Áø(ÇѾçÀÇ´ë)

±³À°½Ã°£ 04¿ù 20ÀÏ ¹é¹ü±è±¸±â³ä°ü (Room B) 15:30~15:50 °æµµÀÎÁöÀå¾Ö ȯÀÚ°ü¸®¸¦ À§ÇÑ Á¤Ã¥ ¹æÇâ ¼­Áö¿ø(Áß¾ÓÄ¡¸Å¼¾ÅÍ)

±³À°½Ã°£ 04¿ù 20ÀÏ ¹é¹ü±è±¸±â³ä°ü (Room B) 15:50~16:10 Áö¿ª »çȸ ÀÎÁö°Ç°­ÁõÁø Ãß±¸ Á¤Ã¥ ¾ç¿µ¼ø/ÇÏűæ(´ëÇÑÄ¡¸ÅÇÐȸ º¸ÇèÀÌ»ç/º¸°Çº¹ÁöºÎ ³ëÀΰǰ­°úÀå)

±³À°½Ã°£ 04¿ù 20ÀÏ ¹é¹ü±è±¸±â³ä°ü (Room B) 16:10~16:30 Global phase3 trial of AR1001 in Early Alzheimer's Diseases: POLARIS-AD Á¤ÀçÁØ(¾Æ¸®¹ÙÀÌ¿À)

±³À°½Ã°£ 04¿ù 20ÀÏ ¹é¹ü±è±¸±â³ä°ü (Room B) 16:30~16:50 KDS2010(Tisolagiline): A novel inhibitor of aberrant GABA production in reactive astrocytes for treatment of neurodegenerative diseases ±è»ó¿í(´º·Î¹ÙÀÌ¿ÀÁ¨)

±³À°½Ã°£ 04¿ù 20ÀÏ ¹é¹ü±è±¸±â³ä°ü (Room B) 16:50~17:10 Double-blind, Placebo-controlled study of the effects of a live biotherapeutic product in preclincal Alzheimer's disease ÃÖ°­È£(Àü³²´ëº´¿ø)

±âŸ 04¿ù 20ÀÏ ¹é¹ü±è±¸±â³ä°ü 17:10~17:30 Closing Remarks ¹× ½Ã»ó½Ä ()

 

  • ÃßõÇϱâ
Tip. ±³À°ÀÏÁ¤Àº ±³À°±â°üÀÇ »çÁ¤¿¡ µû¶ó º¯°æµÉ ¼ö ÀÖÀ¸¹Ç·Î »çÀü¿¡ ¹Ýµå½Ã ±³À°±â°üÀ¸·Î ¹®ÀÇÇÏ¿© È®ÀÎ ¹Ù¶ø´Ï´Ù.
¡å
ÀÛ¼ºÀÚ   ºñ¹Ð¹øÈ£
 
¿¬¼ö°­Á ÁÖ°£º£½ºÆ®
Á¦¸ñ

[¼­¿ï] (¿Â¶óÀÎ) 2024³â Á¦5ȸ ½Å¼ººóÇ÷¿¬±¸È¸ ¿¬¼ö°­Á : 2024-03-09

±³À°ÀÏÀÚ : 2024-03-09 ±³À°Àå¼Ò : (¿Â¶óÀÎ) ±³À°ÁÖÁ¦ : (¿Â¶óÀÎ) 2024³â Á¦5ȸ ½Å¼ººóÇ÷¿¬±¸È¸ ¿¬¼ö°­ÁÂÁÖÃÖ±â°ü : ´ëÇѽÅÀåÇÐȸ ½ÃÇà±â°ü(ÁöºÎ/°ú) : ½Å¼ººóÇ÷¿¬

Ãßõ¼ö : 0 , Á¶È¸¼ö : 894 , ´ñ±Û¼ö : 0

[¼­¿ï] (¿Â¶óÀÎ) Á¦9ȸ ºñ¸¸Àü¹®°¡ ±âÃÊ°úÁ¤ : 2024-04-28

±³À°ÀÏÀÚ : 2024-04-28 ±³À°Àå¼Ò : ¿Â¶óÀÎ ±³À°ÁÖÁ¦ : (¿Â¶óÀÎ) Á¦9ȸ ºñ¸¸Àü¹®°¡ ±âÃÊ°úÁ¤ ÁÖÃÖ±â°ü : ´ëÇѺñ¸¸ÇÐȸ ´ã´çÀÚ : ÃÖÀ±Áö ¿¬¶ôó : 02-6941-087

Ãßõ¼ö : 0 , Á¶È¸¼ö : 832 , ´ñ±Û¼ö : 0

[¼­¿ï] (¿Â¶óÀÎ)Á¦27Â÷ ´ç´¢º´ ±³À°ÀÚ ¿¬¼ö°­Á : 2024-03-30

±³À°ÀÏÀÚ : 2024-03-30 ±³À°Àå¼Ò : ¿Â¶óÀÎ »ýÁß°è ±³À°ÁÖÁ¦ : (¿Â¶óÀÎ)Á¦27Â÷ ´ç´¢º´ ±³À°ÀÚ ¿¬¼ö°­ÁÂÁÖÃÖ±â°ü : ´ëÇÑ´ç´¢º´ÇÐȸ ´ã´çÀÚ : °û¼ÖÀÌ ¿¬¶ôó : 02-71

Ãßõ¼ö : 0 , Á¶È¸¼ö : 1,023 , ´ñ±Û¼ö : 0

[ºÎ»ê] ´ëÇÑ°ñÀýÇÐȸ Á¦50Â÷ Çмú´ëȸ(1ÀÏÂ÷) : 2024-04-26

±³À°ÀÏÀÚ : 2024-04-26 ±³À°Àå¼Ò : ·Ôµ¥È£ÅÚ ºÎ»ê ±³À°ÁÖÁ¦ : ´ëÇÑ°ñÀýÇÐȸ Á¦50Â÷ Çмú´ëȸ(1ÀÏÂ÷)ÁÖÃÖ±â°ü : ´ëÇÑ°ñÀýÇÐȸ ´ã´çÀÚ : Á¤À¯Áø ¿¬¶ôó : 031-551

Ãßõ¼ö : 0 , Á¶È¸¼ö : 748 , ´ñ±Û¼ö : 0

[¼­¿ï] ´ëÇÑÇ÷°ü¿Ü°úÇÐȸ 16th Vascular Ultrasound Seoul Update 2023 Symposium (2ÀÏÂ÷) : 2024-04-21

±³À°ÀÏÀÚ : 2024-04-21 ±³À°Àå¼Ò : °¡Å縯ÀÇ´ë ¼­¿ï¼º¸ðº´¿ø ÁöÇÏ 1Ãþ ´ë°­´ç ±³À°ÁÖÁ¦ : 16th Vascular Ultrasound Seoul Update 2023

Ãßõ¼ö : 0 , Á¶È¸¼ö : 881 , ´ñ±Û¼ö : 0